Abstract
The activation of lymphocytes and monocytes and the concentration of reduction equivalents in serum were studied in a cohort of multiple sclerosis (MS) patients undergoing weekly treatment with 30 microg intramuscular interferon beta-1a for 2 years. The degree of activation of monocytes and lymphocytes and reactive oxygen species (ROS) production was higher in MS patients than in healthy controls and decreased in the course of interferon beta-1a treatment approaching control values. The concentration of reduced sulfhydryls in the serum of MS patients was lower than in healthy controls and the treatment with interferon beta-1a (IFNbeta-1a) raised the levels approaching the values of healthy controls.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Dithionitrobenzoic Acid / metabolism
-
Female
-
Free Radicals
-
Humans
-
Interferon beta-1a
-
Interferon-beta / pharmacology*
-
Interferon-beta / therapeutic use
-
Lymphocytes / drug effects*
-
Lymphocytes / metabolism
-
Male
-
Middle Aged
-
Monocytes / drug effects*
-
Monocytes / metabolism
-
Multiple Sclerosis, Relapsing-Remitting / blood*
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Oxidation-Reduction
-
Reactive Oxygen Species / blood*
-
Sulfhydryl Compounds / blood*
-
Tetradecanoylphorbol Acetate / pharmacology
Substances
-
Free Radicals
-
Reactive Oxygen Species
-
Sulfhydryl Compounds
-
Interferon-beta
-
Dithionitrobenzoic Acid
-
Tetradecanoylphorbol Acetate
-
Interferon beta-1a